ReviewNature reviews. Clinical oncology2014
The oligometastatic state - separating truth from wishful thinking.
Review in Nature reviews. Clinical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 116 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase III Randomized Controlled Trial and Economic Evaluation of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer (SABR-COMET-3)
Colorectal Pulmonary Metastases: Pulmonary Metastasectomy Versus Stereotactic Ablative Radiotherapy: a Phase III Multicenter Randomized Controlled Trial
Who cites it
116 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Bibliometric analysis of stereotactic ablative radiotherapy for oligometastases.Frontiers in medicine · 2026Pooled it
- Stereotactic body radiation therapy on abdominal-pelvic lymph node oligometastases: a systematic review on toxicity.Acta oncologica (Stockholm, Sweden) · 2024Pooled it
- Role of Local Treatment for Oligometastasis: A Comparability-Based Meta-Analysis.Cancer research and treatment · 2022Pooled it
- Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Trial
- Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5.BMC cancer · 2018Trial
- Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.The Lancet. Oncology · 2016Trial
- Comparative effectiveness of thermal ablation, radiotherapy, and surgery for adrenal metastases: a multi-institutional cohort study.European radiology · 2026Article
- [Research Progress and Challenges of Oligometastasis in Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- Cancer Pain: Radiotherapy as a Double-Edged Sword.International journal of molecular sciences · 2025Review
- Preliminary Results of Clinical Experience with Consolidative High-Dose Thoracic Radiotherapy for Patients with Extensive-Stage Small Cell Lung Cancer.Tomography (Ann Arbor, Mich.) · 2025Article
- Full-Body Tumor Response Heterogeneity of Metastatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radiopharmaceutical Therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Survival analysis of patients with metastatic head and neck squamous cell carcinoma treated with metastasis-directed radiotherapy and immunotherapy.Radiation oncology (London, England) · 2025Article
- Practical management of oligometastatic gastric cancer.ESMO gastrointestinal oncology · 2024Review
- Stereotactic radiotherapy for liver oligometastases: a pooled analysis following the estro/eortc consensus recommendations.Clinical & experimental metastasis · 2024Article
- Long-term treatment of metastatic adenoid cystic carcinoma with sequential brachytherapy and stereotactic body radiotherapy.Radiation oncology journal · 2024Article
- Radiation Oncologists' Perspectives on Oligometastatic Disease: A Korean Survey Study.Cancer research and treatment · 2024Article
- Clinical experience of consolidative radiotherapy for localized metastatic non-small cell lung cancer who showed favorable tumor response after systemic treatment.Discover oncology · 2024Article
- Metastases-directed local therapies (MDT) beyond genuine oligometastatic disease (OMD): Indications, endpoints and the role of imaging.Clinical and translational radiation oncology · 2024Article
- Progression-directed therapy in patients with oligoprogressive castration-resistant prostate cancer.Investigative and clinical urology · 2024Article
- Real-world effectiveness and safety of stereotactic body radiotherapy for liver metastases with different respiratory motion management techniques.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2023Article
56 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The oligometastatic paradigm implies that patients who develop a small number of metastatic lesions might achieve long-term survival if all these lesions are ablated with surgery or stereotactic radiotherapy. Clinical data indicate that the number of patients with oligometastatic disease receiving aggressive treatment is increasing rapidly. We examine the key evidence supporting or refuting the existence of an oligometastatic state. Numerous single-arm studies suggest that long-term survival is 'better-than-expected' after ablative treatment. However, the few studies with adequate controls raise the possibility that this long-term survival might not be due to the treatments themselves, but rather to the selection of patients based on favourable inclusion criteria. Furthermore, ablative treatments carry a risk of harming healthy tissue, yet the risk-benefit ratio cannot be quantified if the benefits are unmeasured. If the strategy of treating oligometastases is to gain widespread acceptance as routine clinical practice, there should be stronger evidence supporting its efficacy.
Indexed as
Identifiers
24958182What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.